Buy Latin American real-world data to design phase 2b/3 and select sites
Phase 2b/3 design needs AKI incidence after cardiac surgery, baseline risk and site volumes. Cromodata's hospital network in five Latin American countries can supply de-identified cohorts and identify high-volume sites. Bilix gets cheaper trial design and new geographies; Cromodata gets a named pharma-type buyer.
Evidence from the records
- “Marketplace in operation: claimed network of 47 to 84+ healthcare facilities in 5 countries (Argentina, Uruguay, Mexico, Dominican Rep., Brazil); no data buyer publicly named.”
- “BX-001N: phase 1 completed (51 volunteers, Australia), phase 2a under way in Korea (NCT07164833) with KDDF support.”
- If it works
- A feasibility dataset and shortlisted LatAm sites for later trials.
- First step
- Send Cromodata a cohort definition (cardiac surgery, creatinine follow-up) and request a feasibility count.